Barrett’s oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux

Table 1 Studies summary, sensitivity and specificity of the Cytosponge™-TFF3 test per segment length

Study Ref n#	Publication Year	Study type	Setting	BE length	Sensitivity % (95% CI)	Specificity % (95% CI)
Pilot [14]	2008	Cohort	2^ary care	≥C1	78.0 (64.0–89.0)	94.0 (87.0–98.0)
BEST1 [12]	2010	Prospective	1^ary care	≥C1	73.3 (44.9–92.2)	93.8 (91.3–95.8)
BEST1 [12]	2010	Prospective		≥C2	90.0 (55.5–99.7)	93.5 (90.9–95.5)
BEST2 [13]	2014	Case:control	2^ary care	≥C1	79.5 (75.9–82.9)	92.4 (89.5–94.7)
				≥C2	83.9 (80.0–87.3)
				≥C3	87.2 (83.0–90.6)
CASE1 [15]	2015	Cohort	2^ary care	≥C1 or ≥ M3 ≥C3	95.4 (86.9–98.9) 96.8 (83.7–99.5)	N/A

ISSN: 1471-2407